Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome

Medicine and Dentistry

• Lenalidomide 100%
• Patient 80%
• Toxicity 40%
• Monotherapy 40%
• Mycosis fungoides 40%
• Fatigue 40%
• Syndrome 40%
• Overall Survival 20%
• Systemic Therapy 20%
• Adverse Event 20%
• Progression Free Survival 20%
• Hematologic Malignancy 20%
• Cutaneous T Cell Lymphoma 20%
• Leukopenia 20%
• Infection 20%
• Blood Sampling 20%
• Skin Defect 20%
• Pain 20%
• Therapeutic Procedure 20%
• T Cell 20%
• T-Helper Cell 20%

INIS

• patients 80%
• refractories 60%
• toxicity 40%
• fatigue 40%
• mycoses 40%
• data 20%
• therapy 20%
• size 20%
• skin 20%
• malignancies 20%
• pain 20%
• doses 20%
• blood 20%
• lymphomas 20%
• leukopenia 20%